Moreover, the treatment efficacy of this combination was significantly superior to that of sunitinib in 112 patients with sarcomatoid tumour categorized as WHO/ISUP grade 4 regardless of PD-L1 expression according to the result of the combination of nivolumab plus ipilimumab in RCC patients (CheckMate 214)29. The gene discussed is CD274; the disease is renal cell carcinoma.